Claims
- 1. A method of inhibiting conversion of non-neoplastic ovarian epithelial cells to neoplastic cells comprising administering to a female subject an effective amount of a Vitamin D compound.
- 2. The method of claim 1 wherein Vitamin D compound is administered at a dosage equivalent of from 0.0001 to 1.0 mg 1,25-dihydroxyvitamin D3/kg of body weight.
- 3. The method of claim 2 wherein Vitamin D compound is administered at a dosage equivalent of from 0.005 to 0.1 mg/kg 1,25-dihydroxyvitamin D3 of body weight.
- 4. The method of claim 1 wherein the Vitamin D compound is 1,25-dihydroxyvitamin D3.
- 5. The method of claim 1 comprising concurrent administration of a progestin product.
- 6. The method of claim 1 further comprising concurrent administration of a Vitamin A metabolite.
- 7. The method of claim 6 wherein the Vitamin A metabolite is retinoic acid.
- 8. The method of claim 1 further comprising concurrent administration of dexamethasone.
- 9. The method of claim 1 which includes first determining that such female subject does not display signs of ovarian cancer.
- 10. The method of claim 1 wherein the female subject is at high risk of developing ovarian cancer.
- 11. The method of claim 1 wherein said non-neoplastic cells are dysplastic cells.
- 12. A method of increasing apoptosis in non-neoplastic ovarian epithelial cells of a female subject comprising administering to a female subject an amount of a Vitamin D compound in an amount effective to induce apoptosis in non-neoplastic ovarian epithelial cells of the female subject.
- 13. The method of claim 12 wherein Vitamin D compound is administered at a dosage equivalent of from 0.0001 to 1.0 mg 1,25-dihydroxyvitamin D3/kg of body weight.
- 14. The method of claim 13 wherein Vitamin D compound is administered at a dosage equivalent of from 0.005 to 0.1 mg/kg 1,25-dihydroxyvitamin D3 of body weight.
- 15. The method of claim 12 wherein the Vitamin D compound is 1,25-dihydroxyvitamin D3.
- 16. The method of claim 12 comprising concurrent administration of a progestin product.
- 17. The method of claim 16 wherein the progestin product is administered at a dosage less than or equal to a dosage equivalent to 10.0 mg of norethindrone.
- 18. The method of claim 16 wherein the progestin product is administered at a dosage less than or equal to a dosage equivalent to 1.0 mg of norethindrone.
- 19. The method of claim 18 wherein the progestin product is administered at a dosage less than or equal to a dosage equivalent to 0.2 mg of norethindrone.
- 20. The method of claim 12 further comprising concurrent administration of a Vitamin A metabolite.
- 21. The method of claim 20 wherein the Vitamin A metabolite is retinoic acid.
- 22. The method of claim 12 further comprising concurrent administration of dexamethasone.
- 23. The method of claim 12 wherein the female subject is at high risk of developing ovarian cancer.
- 24. The method of claim 12 wherein said non-neoplastic cells are dysplastic cells.
- 25. A pharmaceutical composition for inhibiting the conversion of non-neoplastic ovarian epithelial cells to neoplastic cells comprising a Vitamin D compound and a hormone product.
- 26. The pharmaceutical composition of claim 25 wherein said hormone is a progestin product.
- 27. The pharmaceutical composition of claim 26 wherein the Vitamin D compound is present at a dosage equivalent of from 0.0001 to 1.0 mg 1,25-dihydroxyvitamin D3/kg of body weight and wherein the progestin product is present at a dosage less than or equal to a dosage equivalent to 10.0 mg of norethindrone and wherein said composition is a single unit dosage.
- 28. The pharmaceutical composition of claim 27 wherein the Vitamin D compound is present at a dosage equivalent of from 0.005 to 0.1 mg 1,25-dihydroxyvitamin D3/kg of body weight and wherein the progestin product is present at a dosage less than or equal to a dosage equivalent to 1.0 mg of norethindrone.
- 29. The pharmaceutical composition of claim 25 wherein said hormone product is effective to provide contraceptive protection and wherein said composition is a single unit dosage.
- 30. The pharmaceutical composition of claim 29 wherein said hormone product comprises estrogen and progestin.
- 31. The pharmaceutical composition of claim 29 wherein said hormone product compound comprises estrogen.
- 32. The pharmaceutical composition of claim 25 wherein said hormone product is effective for hormonal replacement in post-menopausal women and said composition is a single unit dosage.
- 33. The pharmaceutical composition of claim 32 wherein said hormone product comprises estrogen.
- 34. The pharmaceutical composition of claim 32 wherein said hormone product includes estrogen and progestin.
FIELD OF THE INVENTION
[0001] This application is a continuation-in-part of U.S. Ser. No. 08/713,834 filed Sep. 13, 1996. The present invention relates generally to methods of preventing the development of ovarian cancer by administering Vitamin D compounds including Vitamin D, and biologically active analogues and derivatives thereof.
Continuations (3)
|
Number |
Date |
Country |
Parent |
10051662 |
Jan 2002 |
US |
Child |
10781173 |
Feb 2004 |
US |
Parent |
09479837 |
Jan 2000 |
US |
Child |
10051662 |
Jan 2002 |
US |
Parent |
08073010 |
Jun 1993 |
US |
Child |
09479837 |
Jan 2000 |
US |